Gene NHL Patients (number-%) Controls (number-%) OR 95% CI P value
CASP8 D302H
Wild genotype CC
• Heterotype
CG
• Homotype GG

• CG and GG
9(9%)
7(7%)
84(84%)
91(91%)
49(49%)
6(6%)
45(45%)
(51%)
Reference
1.179
6.417
9.715
0.382-3.641
3.303-12.466
4.413-21.387
0.774
<0.001
<0.001
CAS8 6N 652 ins/del
Wild genotype ins/ins
• Heterotype ins/del

Homotype del/del
Ins/del and del/del
19(19%)
44(44%)
37(37%)
81(81%)
20(20%)
46(46%)
34(34%)
80(80%)
Reference
0.966
1.140
0.886
0.55-1.677
0.639-2.035
0.508-1.546
0.887
0.658
0.671
CASP 10 I522L
• Wild genotype TT
• Heterotype
TA
• Homotype AA

• TA and AA
48(48%)
43(43%)
9(9%)
52(52%)
45(45%)
41(41%)
14(14%)
55(55%)
Reference
1.08
0.608
0.938
0.619-1.904
0.250-1.476
0.466-1.889
0.774
0.268
0.858
Dual CASP8 D302H / CASP8-652 6N ins/del mutation 74(74%) 40(40%) 4.269 2.344-7.777 <0.0001
Dual CASP 8 D302H / CASP10 I522L mutation 47(47%) 31(31%) 1.974 1.108-3.517 0.020
Dual CASP 8-652 6N ins/del /CASP 10 I522L mutation 39(39%) 40(40%) 0.959 0.959-0.554 0.885
Triple mutation 35(35%) 24 (24%) 1.705 0.921-3.157 0.088
p-value <0.05=significant
Table 4: The frequency of CASP8- D302H, CASP8- 652 6N ins/del, and CASP10- I522L genotypes in NHL patients and controls.